These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25164322)

  • 1. Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas.
    Mäkelä K; Nordfors K; Finne J; Jokilammi A; Paavonen T; Haapasalo H; Korja M; Haapasalo J
    BMC Cancer; 2014 Aug; 14():623. PubMed ID: 25164322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
    Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
    Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
    Abd El-Hafez A; Ismail Hany HSED
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activation in astrocytomas: deposition of C4d and patient outcome.
    Mäkelä K; Helén P; Haapasalo H; Paavonen T
    BMC Cancer; 2012 Dec; 12():565. PubMed ID: 23199209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
    J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma.
    Korja M; Jokilammi A; Salmi TT; Kalimo H; Pelliniemi TT; Isola J; Rantala I; Haapasalo H; Finne J
    BMC Cancer; 2009 Feb; 9():57. PubMed ID: 19222860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between IDH1 mutation and prognosis in supratentorial high-grade astrocytomas].
    Xie F; Tang JJ; Wang X; Liu YH; Mao Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 44(2):184-7, 192. PubMed ID: 23745251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
    Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
    Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Interactions of the Polysialytransferase Domain (PSTD) in ST8Sia IV with CMP-Sialic Acid and Polysialic Acid Required for Polysialylation of the Neural Cell Adhesion Molecule Proteins: An NMR Study.
    Liao SM; Lu B; Liu XH; Lu ZL; Liang SJ; Chen D; Troy Ii FA; Huang RB; Zhou GP
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
    Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL
    Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
    Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
    Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
    Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
    Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy Number Profiling of Brazilian Astrocytomas.
    Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
    G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
    Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
    Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
    Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.